Management of Castration Resistant Prostate Cancer

2014
ISBN: 978-1-4939-1175-2
Verlag: Springer US

Buch, Englisch, 337 Seiten, Format (B × H): 183 mm x 260 mm, Gewicht: 8924 g

Reihe: Current Clinical Urology

This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in depth review of proven therapeutic options, including bone targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigations are also reviewed. The text provides up to date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence based medicine.

As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this challenging malignancy.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Eisenberger, Mario A.

Saad, Fred

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Bildgebende Verfahren, Nuklearmedizin, Strahlentherapie Radiologie, Bildgebende Verfahren
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Urologie, Andrologie, Venerologie

Inhaltsverzeichnis

Introduction - Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities.- Evolution of Clinical States and the Castration Resistant Clinical Paradigm.- Molecular Mechanisms of Prostate Cancer Progression after Castration.- New Imaging Modalities.- Androgen Receptor Biology in Castration Resistant Prostate Cancer.- The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer.- Approaches Targeting Androgen Synthesis (CYP 17 inhibitors).- Cytotoxic Chemotherapy (Taxanes and Taxane Combinations).- The Emerging Role of Immunotherapy in Castrate Resistant Prostate Cancer.- Bone Targeted Therapy: Rationale and Current Status.- Radium-223 and Other Radiopharmaceuticals in Prostate Cancer.- Introduction.- Phase I/II targeted treatments.- Defining Clinical Endpoints in Castration-resistant Prostate Cancer.- Angiogenesis Inhibition in Castration Resistant Prostate Cancer.- Co-targeting Adaptive Survival Pathways.- Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer.- PARP Inhibitors.- Targeting C-Met/VEGF in Castration Resistant Prostate Cancer.- Epigenetics in Castration Resistant Prostate Cancer.- Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype.- Strategies Addressing Quality of Life: Patient Reported Outcome and Symptoms Management.- Evidence-Based Therapeutic Approaches for mCRPC patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development.

Über Autor(innen)

Fred Saad, MD, FRCS
Professor and Chief of Urology, Director of GU Oncology, University of Montreal Endowed Chair in Prostate Cancer, University of Montreal Hospital Center, Department of Surgery, Division of Urology, Montreal, Quebec, Canada.

Mario A. Eisenberger, MD
R. Dale Hughes Professor of Oncology and Urology, The Johns Hopkins University, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.